VNA
ATNM icon

Valley National Advisers’s Actinium Pharmaceuticals ATNM Stock Holding History

Valley National Advisers’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-67
Closed -$1K – 773
2020
Q2 		$1K Buy
+67
New +$507 ﹤0.01% 692

Other funds holding ATNM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Valley National Advisers's ATNM Position: Q3 2020 in Review

Valley National Advisers sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 67 shares — an estimated $1K sold.

Valley National Advisers first reported a position in ATNM in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

  • Valley National Advisers reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Valley National Advisers sold 67 Actinium Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • Valley National Advisers first reported a position in Actinium Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Valley National Advisers's Actinium Pharmaceuticals position peaked at $1K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on Valley National Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.